Bioptigen, a medical device firm that developed and commercialized a non-invasive scanning technology for ophthalmic procedures, has caught the eye of a German diagnostics company now set to buy the startup.
MIAMI — Breast-feeding a baby for at least six months may be linked to a lower risk of childhood leukemia, according to a review presented Monday by Israeli researchers of previously published research on the topic.
The findings in the Journal of the American Medical Association (JAMA) Pediatrics suggest that breast-fed babies have a 19 percent lower risk of the blood cancer compared to babies who are given formula or who are breast-fed for a shorter period of time.
Freedom Meditech, a San Diego medical diagnostic company, said it has raised $4.8 million in a Series C financing round, bringing total venture funding to about $14 million in the nine years since the company was founded.
The company also named John Gerace as CEO and as a member of the company’s board of directors.
Gerace previously headed the applied sciences division of Carlsbad, CA-based Life Technologies, leaving at the beginning of 2014 as Waltham, MA-based Thermo Fisher Scientific completed its $13.6 billion acquisition of Life Technologies. Before that, Gerace served as vice president and general manager of the PCR systems business at Life Technologies.
Anyone who has taken care of aging parents or family members knows the agony of navigating all the doctors, insurance claims, and post-hospital care. That last one is its own special nightmare: once patients are discharged, they are basically on their own to find the right rehab facility, nursing home, or home healthcare agency.
And guess where that often leads? Right back to the hospital, which is a huge problem for everyone involved, especially the patient.
L'Université Carlos III de Madrid et l'Institut de Recherche de l'Hôpital Ramon et Cajal ont déposé un nouveau brevet pour un dispositif réalisant des biopsies cutanées. Le nouvel outil simplifie la procédure et diminue le temps d'intervention, le réduisant à 30 minutes, voire dans le meilleur des cas 5 minutes. Il permet d'effectuer l'opération sans anesthésie locale ni personnel hautement spécialisé, et ainsi d'accélérer le diagnostic de pathologies tel que le cancer de la peau.
La iniciativa, denominada HTScreentech, tiene el objetivo de diseñar una plataforma que posibilite un cribado más rápido y barato que permita determinar fármacos, denominados en el ámbito científico ligandos, para receptores muscarínicos.
La compañía vizcaína IMG PHARMA Biotech, especializada en el desarrollo de nuevas herramientas para el análisis molecular, lidera un proyecto que busca diseñar una plataforma biotecnológica para el cribado de fármacos.
Du 20 au 22 mai dernier se tenait à Stanford la seconde édition d'une conférence intitulée Big Data in Biomedicine, visant, comme son nom l'indique, à présenter l'état de l'art de la révolution grandissante qui secoue le secteur de la santé du fait de l'essor exponentiel de nouvelles technologies ouvrant de nouveaux champs entiers de recherche. Ce fut l'occasion de prendre un cliché saisissant des avancées de pointe de la recherche biomédicale américaine et, plus encore, de saisir l'ampleur des changements structurels, réglementaires, techniques et même psychologiques qu'engendre cette ère nouvelle qui débute.
Novartis AG has an extensive line of biologic drugs that can only be taken by injection, but now the pharmaceutical giant is making a bet on a “robotic pill,” a preclinical product that could make drugs like insulin available for the first time without the use of a needle.
Online health management company Keas is announcing a new personal health platform that gamifies health care, making it more fun for people to track and improve their health over time.
U.S. businesses spend more than $620 billion a year on employer-sponsored health care, and that number is expected to exceed $1 trillion in the next five years, according to The Kaiser Family Foundation and Constellation Research. Keas figures its SmartHealth Engine and Keas+ upgrades will help improve engagement, make people healthier, and reduce employer health care costs.
The number Europeans living with hepatitis B and C is growing, particularly in Eastern Europe. But access to treatments remains scarce, due to funding problems and a lack of awareness of the problem, say patient groups.
Over the past four decades, there has been a significant increase in Europeans affected by hepatitis B and C. These diseases kill around 120,000 people in Europe every year. However, in the case of hepatitis C, many are unaware that they have the disease, caused by a virus that primarily affects the liver, as hepatitus is often asymptomatic and progresses slowly.
